Antimicrobial resistance (AMR) is a direct threat to global public health. If we do not take steps to curb AMR, current antimicrobials, including both antibiotics and antifungals, will become ineffective against infections and infectious diseases and render routine medical procedures, such as hip replacements, cesarean sections, and root canals, too risky to perform. Without immediate, focused, and coordinated actions to curb the spread of AMR, treating infections will become increasingly complex, if not impossible.

As one of the largest private-sector coalitions representing the life sciences industry, the AMR Industry Alliance uniquely understands the complexities of the AMR challenge. We recognize that fighting AMR requires a broad, multi-stakeholder approach and reaffirm that the 2030 agenda for the Sustainable Development Goals offers a framework to ensure healthy lives and promote well-being for all ages.

We also recognize that the private sector is critical in setting the agenda and taking action. Current diagnostics and antimicrobials are key resources in the fight against AMR, and the appropriate utilization of what’s available worldwide is as critical as the innovation of current and new antimicrobials.
Therefore, on the occasion of the second UN High-level Meeting on Antimicrobial Resistance in September 2024, the AMR Industry Alliance calls on the UN and its Member States to commit to increase their efforts in the fight against AMR, to work with stakeholders in the public and private sectors to identify and prioritize risk-based solutions to drastically curb the spread of AMR, and to include them in the high-level declaration on AMR. Further, the AMR Industry Alliance calls on the UN and its Member States to:

1. Adopt the Antibiotic Manufacturing Standard as part of their tendering and reimbursement policies and incentivize antibiotic manufacturers and suppliers to be certified per the standard through third-party certification.

2. Transform the market for antimicrobials with new incentives that encourage companies, investors, and researchers to pursue ongoing antimicrobial innovation and market launch.

3. Take actionable steps to ensure equitable access to antimicrobials around the world by removing barriers to registration, accelerating approvals, improving forecasting through better data collection and surveillance, and reforming antimicrobial procurement practices.

4. Improve the appropriate use of antimicrobials by utilizing diagnostic tests and implementing stewardship programs, prioritizing investments in laboratory infrastructure, improving the valuation of diagnostics based on their short- and long-term value, expanding surveillance of AMR at the local, national, and global levels, and establishing consensus on meaningful and feasible AMS metrics to track progress.

ABOUT THE AMR INDUSTRY ALLIANCE

The AMR Industry Alliance is one of the largest private-sector coalitions established to provide sustainable solutions to curb antimicrobial resistance. The Alliance, comprised of 77 biotechnology, diagnostics, generics, and research-based pharmaceutical companies and 10 trade associations, facilitates collaboration, reports on the industry’s contribution to the fight against AMR, and engages with external stakeholders. The Alliance seeks to contribute sustainable solutions to curb antimicrobial resistance by creating broad industry momentum and facilitating collaboration between the public and private sectors.

The Alliance, in its diversity of membership incorporating the full spectrum of life sciences companies and associations, serves as a unique industry voice and facilitator of industry progress. It produces annual reports on its activities and the activities of its members and drives progress through its working groups on access, appropriate use, research and science, and manufacturing.